Thyrotoxicosis Symptoms: What Could Be Causing Them and What to Do Next

Thyrotoxicosis vs. Hyperthyroidism: A Distinction That Changes the Workup

These two terms are not interchangeable, and confusing them leads to the wrong diagnostic path. Thyrotoxicosis is the clinical syndrome of excess circulating thyroid hormone from any source. Hyperthyroidism is a subset where the thyroid gland itself is synthesizing and secreting too much hormone.

The distinction matters because treatment depends on the mechanism. A patient with Graves disease (true hyperthyroidism) may need antithyroid drugs or radioactive iodine ablation. A patient with subacute thyroiditis (thyrotoxicosis without hyperthyroidism) needs supportive care while stored hormone clears from the bloodstream. The American Thyroid Association (ATA) 2016 guidelines for hyperthyroidism management state: "The distinction between thyrotoxicosis caused by hyperthyroidism and that caused by thyroiditis is critical, as the treatment approaches are fundamentally different" [1]. Misclassifying the etiology can expose patients to unnecessary procedures or delay appropriate treatment. The radioactive iodine uptake (RAIU) scan is the single most useful test for separating these two categories. High uptake (above 35%) points to true hyperthyroidism. Low or absent uptake points to thyroiditis, exogenous hormone ingestion, or ectopic thyroid tissue [1].

Graves Disease: The Most Common Cause

Graves disease accounts for 60 to 80 percent of all hyperthyroidism cases in iodine-sufficient regions, according to data published in the New England Journal of Medicine [2]. It is an autoimmune condition in which thyroid-stimulating immunoglobulins (TSI) bind to and activate the TSH receptor on thyroid follicular cells.

Women are affected five to ten times more often than men. Peak onset occurs between ages 30 and 50. The classic triad includes diffuse goiter, ophthalmopathy (present in about 25 to 30% of patients), and pretibial myxedema (present in 1 to 2%). Not every patient presents with all three features. Some present only with weight loss and anxiety. Others present with atrial fibrillation, particularly patients over age 60.

Lab findings typically show a suppressed TSH (often <0.01 mIU/L), elevated free T4, and positive TSI or thyrotropin receptor antibodies (TRAb). The RAIU scan shows diffusely increased uptake. A 2023 retrospective analysis published in The Journal of Clinical Endocrinology & Metabolism found that TRAb had a sensitivity of 97% and specificity of 99% for Graves disease, making it a reliable diagnostic marker even when imaging is deferred [3].

Treatment options include methimazole (first-line in most non-pregnant patients, starting dose 10 to 30 mg daily), radioactive iodine (RAI) ablation, or thyroidectomy. The ATA guidelines recommend methimazole for 12 to 18 months as initial therapy, with remission rates of approximately 40 to 50% after a single course [1].

Toxic Multinodular Goiter and Toxic Adenoma

These are the second and third most common causes of hyperthyroidism, respectively. Toxic multinodular goiter (TMNG) predominates in older adults and in regions with historical iodine deficiency. Toxic adenoma is a single autonomously functioning thyroid nodule.

Both conditions produce excess thyroid hormone independent of TSH stimulation. The RAIU scan in TMNG shows patchy, irregular uptake with "hot" and "cold" areas. In toxic adenoma, a single hot nodule concentrates iodine while the surrounding tissue is suppressed. TSI and TRAb are negative, which distinguishes these conditions from Graves disease.

TMNG rarely remits spontaneously. A study in the European Journal of Endocrinology reported that fewer than 5% of patients with TMNG achieved euthyroidism without definitive treatment [4]. RAI ablation or surgery are the standard definitive therapies. Methimazole can control symptoms but does not produce lasting remission in nodular disease. For patients who are poor surgical candidates, RAI doses for TMNG are typically higher (15 to 30 mCi) than those used for Graves disease (10 to 15 mCi) [1].

Thyroiditis: When the Gland Leaks Rather Than Overproduces

Thyroiditis causes thyrotoxicosis through destruction of thyroid follicular cells and release of preformed hormone into the circulation. The gland is not overproducing hormone. It is losing it. This is why RAIU is low or near zero.

Several subtypes exist:

Subacute (de Quervain) thyroiditis follows a viral upper respiratory infection in most cases. Patients report anterior neck pain radiating to the jaw or ears, fever, and malaise. The thyrotoxic phase lasts 3 to 6 weeks, followed by a hypothyroid phase of similar duration, then recovery. Erythrocyte sedimentation rate (ESR) is often elevated above 50 mm/hr. NSAIDs are first-line; prednisone 40 mg daily tapering over 4 to 6 weeks is used for severe pain [5].

Painless (silent) thyroiditis is autoimmune in origin and clinically resembles subacute thyroiditis without the neck pain or elevated ESR. It accounts for about 1% of thyrotoxicosis cases. A postpartum variant occurs in 5 to 10% of women within 12 months of delivery [6].

Drug-induced thyroiditis is increasingly recognized. Amiodarone causes thyrotoxicosis in 3 to 5% of treated patients through two distinct mechanisms: type 1 (iodine-induced excess synthesis in patients with underlying thyroid disease) and type 2 (direct thyroid destruction). Immune checkpoint inhibitors, including pembrolizumab and nivolumab, trigger destructive thyroiditis in 5 to 10% of patients receiving these agents, per a 2021 meta-analysis in Thyroid [7].

Exogenous Thyroid Hormone: The Overlooked Cause

Thyrotoxicosis factitia occurs when a patient ingests supraphysiologic doses of thyroid hormone. This may be intentional (weight loss attempts, bodybuilding protocols) or iatrogenic (over-replacement in hypothyroid patients, TSH suppression therapy for thyroid cancer). The prevalence is likely underreported.

The clinical clue is a suppressed TSH with low thyroglobulin levels. Endogenous overproduction of thyroid hormone raises thyroglobulin. Exogenous ingestion suppresses it. A thyroglobulin level below 5 ng/mL in the setting of thyrotoxicosis should raise suspicion for exogenous hormone intake [8]. RAIU is low or absent, which can mimic thyroiditis. A careful medication history is the most efficient diagnostic step.

Dr. Douglas Ross, Professor of Medicine at Harvard Medical School, has written: "Factitious thyrotoxicosis should be considered in any patient with thyrotoxicosis, low RAIU, and a suppressed serum thyroglobulin" [8].

The Diagnostic Algorithm: From TSH to Definitive Diagnosis

The initial evaluation of suspected thyrotoxicosis begins with serum TSH. A normal TSH effectively excludes clinically significant thyrotoxicosis in most ambulatory patients (sensitivity exceeds 98%) [1].

If TSH is suppressed (below 0.4 mIU/L), the next step is free T4 and free T3. Three patterns emerge. First, suppressed TSH with elevated free T4 constitutes overt thyrotoxicosis. Second, suppressed TSH with normal free T4 but elevated free T3 indicates T3 thyrotoxicosis, seen in about 5% of hyperthyroid patients and common in early Graves disease and toxic adenoma [2]. Third, suppressed TSH with normal free T4 and normal free T3 defines subclinical hyperthyroidism.

Once biochemical thyrotoxicosis is confirmed, the RAIU scan separates the differential. High uptake (diffuse) points to Graves disease. High uptake (focal or patchy) points to toxic adenoma or TMNG. Low uptake points to thyroiditis, exogenous hormone, or rare causes such as struma ovarii.

TRAb or TSI testing can substitute for RAIU when scanning is unavailable, contraindicated (pregnancy), or when the clinical picture strongly suggests Graves disease. The 2016 ATA guidelines allow TRAb as an alternative first-line diagnostic test in this setting [1].

Symptom Patterns That Point to Specific Causes

The core symptoms of thyrotoxicosis overlap regardless of etiology: tachycardia, weight loss, heat intolerance, tremor, anxiety, and diarrhea. Certain clinical features, though, favor specific diagnoses.

Ophthalmopathy (lid retraction, proptosis, periorbital edema) is virtually pathognomonic for Graves disease. Anterior neck pain with fever suggests subacute thyroiditis. A palpable single nodule in a young patient raises suspicion for toxic adenoma. Atrial fibrillation as the presenting symptom is more common in older patients with TMNG. Recent use of amiodarone, lithium, iodinated contrast, or checkpoint inhibitors should prompt evaluation for drug-induced thyroiditis.

A 2019 population-based study in Denmark (N=235,547) found that patients over age 60 with thyrotoxicosis were 3.1 times more likely to present with atrial fibrillation than patients under 40, and significantly less likely to report classic adrenergic symptoms like tremor and anxiety [9]. This "apathetic thyrotoxicosis" in older adults can delay diagnosis.

When to Worry: Red Flags That Require Urgent Evaluation

Most thyrotoxicosis is managed in the outpatient setting. Several presentations require urgent or emergent evaluation.

Thyroid storm is a life-threatening exacerbation with fever above 38.5°C, tachycardia exceeding 140 bpm, altered mental status, and organ dysfunction. Mortality ranges from 10 to 30% even with aggressive treatment in an ICU setting [10]. The Burch-Wartofsky Point Scale (BWPS) quantifies clinical severity; a score above 45 is highly suggestive of thyroid storm. Treatment includes propylthiouracil (PTU) 500 to 1,000 mg loading dose (preferred over methimazole in storm because PTU also inhibits peripheral T4-to-T3 conversion), iodine solution (given at least one hour after PTU), hydrocortisone 100 mg IV every 8 hours, propranolol, and supportive cooling measures [1].

New-onset atrial fibrillation with rapid ventricular response in the setting of thyrotoxicosis requires rate control (propranolol or diltiazem) and anticoagulation assessment. Chest pain, dyspnea, or signs of heart failure warrant cardiology consultation.

Severe ophthalmopathy with vision changes, marked proptosis, or inability to close the eyelids requires urgent ophthalmology referral. A clinical activity score of 3 or higher on the European Group on Graves Orbitopathy (EUGOGO) scale warrants consideration of IV methylprednisolone pulse therapy [11].

Treatment by Cause: Matching the Intervention to the Mechanism

For Graves disease, the three definitive options are antithyroid drugs, RAI, and surgery. In North America, RAI has historically been the most common choice, but a global shift toward methimazole as first-line therapy has occurred over the past two decades. The ATA 2016 guidelines present all three as reasonable first-line options and recommend shared decision-making [1].

For toxic adenoma and TMNG, RAI or surgery are the definitive therapies. Methimazole is used as bridge therapy to achieve euthyroidism before definitive treatment but does not induce remission.

For thyroiditis, treatment is supportive. Beta-blockers control adrenergic symptoms. NSAIDs or corticosteroids manage pain in subacute thyroiditis. The thyrotoxic phase is self-limited (typically 2 to 8 weeks). Patients should be monitored for the subsequent hypothyroid phase, which may require temporary levothyroxine replacement.

For exogenous thyrotoxicosis, dose reduction or discontinuation of the thyroid hormone source is the treatment. In patients on TSH suppression therapy for differentiated thyroid cancer, the target TSH range should be reassessed in collaboration with oncology.

Beta-blockers provide symptomatic relief across all etiologies. Propranolol 20 to 40 mg every 6 to 8 hours is the most commonly used agent because it also inhibits peripheral T4-to-T3 conversion at higher doses. Atenolol 25 to 50 mg daily is an alternative for patients who need a cardioselective agent [1].

Subclinical Hyperthyroidism: When TSH Is Low but Hormones Are Normal

Subclinical hyperthyroidism affects approximately 0.7% of the U.S. population according to NHANES III data [12]. TSH is suppressed below the reference range, but free T4 and free T3 remain within normal limits.

The clinical significance depends on the degree of TSH suppression. A TSH below 0.1 mIU/L (grade 2) carries a higher risk of atrial fibrillation and osteoporotic fracture than a TSH between 0.1 and 0.4 mIU/L (grade 1). A meta-analysis of 10 cohort studies (N=52,674) published in JAMA found that subclinical hyperthyroidism with TSH <0.1 mIU/L was associated with a 2.54-fold increased risk of atrial fibrillation and a 1.38-fold increased risk of hip fracture [13].

Treatment of grade 2 subclinical hyperthyroidism is recommended for patients over age 65, those with cardiac risk factors, and postmenopausal women not on bone-protective therapy. For grade 1 disease, observation with serial TSH monitoring every 6 to 12 months is appropriate in most patients [1].

Thyrotoxicosis in Pregnancy: Special Considerations

Gestational transient thyrotoxicosis occurs in 1 to 3% of pregnancies, driven by the structural similarity between hCG and TSH. It is most common in the first trimester, peaks between weeks 8 and 11, and resolves by week 14 to 18 as hCG levels decline. It does not require antithyroid drugs [14].

Graves disease complicating pregnancy requires treatment to prevent maternal and fetal complications, including preeclampsia, preterm delivery, and fetal thyrotoxicosis from transplacental passage of TSI. PTU is preferred in the first trimester because methimazole has been associated with rare embryopathy (aplasia cutis, choanal atresia). After the first trimester, switching to methimazole is often recommended given the lower hepatotoxicity risk. Target free T4 should be kept at or just above the upper limit of the trimester-specific reference range, using the lowest effective antithyroid drug dose [1][14].

RAI is absolutely contraindicated in pregnancy due to fetal thyroid ablation risk. RAIU scanning is also contraindicated. TRAb measurement is the preferred diagnostic tool when Graves disease needs to be confirmed during pregnancy [1].

Postpartum thyroiditis affects 5 to 10% of women and typically follows a biphasic course: thyrotoxicosis at 1 to 6 months postpartum, then hypothyroidism at 4 to 8 months, with most women returning to euthyroidism by 12 months. About 20 to 30% develop permanent hypothyroidism requiring lifelong levothyroxine [6].